DDInter1765 DDInter1676
Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Teniposide {u} (Compound) resembles {v} (Compound) Podofilox
Teniposide {u} (Compound) treats {v} (Disease) lung cancer
Teniposide {u} (Compound) binds {v} (Gene) CYP2C9
Teniposide {u} (Compound) upregulates {v} (Gene) EDEM1
Teniposide {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Teniposide {u} (Compound) downregulates {v} (Gene) CLTC
Teniposide {u} (Compound) causes {v} (Side Effect) Flushing
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Teniposide (Compound) resembles Podofilox (Compound)
Teniposide (Compound) treats lung cancer (Disease)
Teniposide (Compound) binds CYP2C9 (Gene)
Teniposide (Compound) upregulates EDEM1 (Gene)
Teniposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Teniposide (Compound) downregulates CLTC (Gene)
Teniposide (Compound) causes Flushing (Side Effect)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Delavirdine
Teniposide may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa